生命科学资讯

Altesa, run by former Trump official, raises $75M for well-traveled lung drug

FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals

Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6

FDA accepts BMS protein degrader for review; Disc rare disease drug rejected

An Alzheimer’s startup emerges with $175M in venture backing

Psychedelics stocks rise as Compass’ psilocybin drug heads to FDA

FDA reverses course on Moderna’s flu vaccine

Compass, with Phase 3 hits, ready to take psilocybin to the FDA

Ocular claims a win with eye drug data even as shares sink

How to evaluate prospective diagnostic laboratory partners for your patient support program

Selecting the optimal cell therapy manufacturing platform

Vertex’s CRISPR therapy rebounds in latest earnings

Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs

FDA removes box warning for 6 menopausal therapies

Ultragenyx cuts jobs as it seeks path to profit in 2027

Moderna shares jump as company affirms growth outlook

Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor

Seres to lay off staff, pause top program in latest reboot

Lowering drug costs is on Republicans’ minds. Democrats say GOP policies don’t help.

Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo